Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8886045 | 0.82 | CDK1 (0.43) | CCNA2CDK2CCNA1 | |
| SCHEMBL17824203 | 0.82 | CDK1 (0.33) | CCNA2CDK2CCNA1 | |
| SCHEMBL7809926 | 0.82 | TSHR (0.37) | CCNA2CDK2CCNA1 | |
| SCHEMBL536980 | 0.73 | DPP4 (0.34) | — | |
| SCHEMBL8884479 | 0.73 | — | — | |
| SCHEMBL536868 | 0.73 | — | — | |
| SCHEMBL16828162 | 0.63 | CCNA2 (0.50) | CCNA2CDK2CCNA1 | |
| SCHEMBL4058597 | 0.62 | — | — | |
| SCHEMBL4860847 | 0.62 | CHEK1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL16828222 | 0.61 | CCNA2 (0.48) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946243-B2 | Compounds and methods for the treatment of viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-02-03 | — | — | US | disclosed |
| US-20110184003-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 2011-07-28 | — | — | US | disclosed |
| EP-2274311-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009142827-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184003-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | TPMT, TYMP, MTAP | CCNA2 1437/4885CDK2 745/4885CCNA1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.